London South East | The UK's favourite investor portal.

TT, TS - You might be right, but you don't seem to give much credit for how far down the track Ciz has come - it's been a long long way and they're now sitting with their test ready to run at scale in a COLA accredited CLIA certified clinical lab in the USA. They don't (as usual) say what the delay is, so anybody's guess, might be waiting for the reimbursement codes or the FDA are now insisting on closer scrutiny of all novel LDTs...who knows. I'd guess from this afternoon's CIZZLE BIO release mentioning that there have been "months of collaboration" between Cizzle Bio, Cizzle Biotechnology Holdings plc (UK), and iGenomeDX" to get the test ready to run (at scale) and they've now announced that they've achieved this milestone probably means that the delay is out of their hands and they're waiting on something external - which might explain why they couldn't give a precise start date. Could be soon, could be later. It's a very different kettle of fish to the other potential early lung cancer tests that we were hearing about late last year that presumably have several more years to get to a similar stage. Given that Cizzle Bio Inc have signed up to give CIZ large cash payments this summer/next year, and given they that they were attending all the relevant lung cancer conferences in the USA last year, I'd imagine they would have heard on the grapevine if some major pharmaceutical giant or other group had a rival early stage test about to appear. Sure, this investment is still a big risk until the test is up & running, assessing 100s of patients blood and proving its worth, but I think we're now on the doorstep.

09.44/10.02 - I’ve the same disappointments as Torp esp as in those heady late Jan early Feb days when the CTL team had apparently disappeared off to Oz for the imminent ASX listing I pulled out all the stops and stretched to the limit to buy more shares before the listing completed … only to find out with the raise that the team probably had already cancelled their trip having heard of Esplin’s backtrack. One comment of DF-D in the last InvestorMeet makes me wonder whether they were deliberately misleading about the trip still taking place in order to get their needed raise in at a better price, so I feel scammed. And Gawd knows why they then decided to extend the Retail offer, as it implied there had been feeble uptake and the long delay in closing the offer has just worsened the situation by the day. Such is.

On the cheerful side, however, if one looks at the story from the potential strategic partner level rather than from the burned private investor, little has changed and the storyline remains very attractive. CTL have a great lithium source, mineable at shallow depth (cheaper to mine), proven purity, proven DLE ability to extract, local facilities & infrastructure etc fairly readily accessible and based in a mining oriented country which has a FTA with the USA, and the lithium being produced has excellent green tech credentials for the European market. The team on the ground from the Chairman/acting CEO downwards are experienced and professional, and amongst other things had the foresight to bring the local indigenous and political communities along with them right from the start. CTL was among the very few chosen by the government for fast track CEOL status, and as Gordon (CFO) said, the CTL submitted an extremely detailed document for the application and it's unlikely that the other fast-tracked applicants would be in any position to be able to produce anything remotely comparable. So it's likely the CEOLs progress to direct negotiation in April, which basically means they’ll be awarded, bearing in mind Chile wants to show the world that it’s “open for business” and CTL have been ticking all the boxes. Having a good CEO & the ASX listing would obviously be a bonus, but in due course it will happen, so I doubt it's a big concern for the strategics, especially as some might want to have their own CEO. On top of it all, the Company’s currently dirt cheap. What’s not to like about the storyline?

So although I mutter & groan, I suspect that interest among the potential strategics to examine the imminent PFS is extremely high, and that bodes well for us. It means I'm patiently holding rather than abandoning ship, albeit regretting not being in any position to add more at this cheap price to average down.

Surely has to be news on one of the publicised imminent events? We were told that the CEOL applications would be submitted in early January (even though the Government deadline is at the end of January), we also were told that the ASX listing with its raise would only be announced AFTER the event completed (I think they called it the "pathfinder" route) so there'll be no prior publicity of when it's about to happen nor at what price new shares would be offered at, nor how many although they said that if the global lithium price & CTL sp hasn't risen substantially before the event then they would skew it towards a minimum cash raise. Both previous Investor Meetings on 6th & 28th Nov pointed to the ASX listing happening straight after the Australian Xmas/summer holidays to ensure best coverage which could imply early February as that's when the school holiday period has ended, but the words Daniel F-D used at the end of the Nov 6th meeting were "straight after the New Year" and SK said at the end of November "very very soon" - so I've been expecting to hear something about it around now or the next week... And lastly, in mid December they mentioned that samples of the first lithium carbonate batch that had been produced in Chicago with Conductive Energy would be sent to a lab for analysis of the grade and impurity profile ... So I'm imagining that the forthcoming investor meet has to be about one of those three things.

Past experience with CTL has shown that there are always unanticipated delays that have occurred so an unwelcome fourth possibility is that they're announcing that - but I'm imagining that's by far the least likely scenario.

Logically they might prefer to announce CEOLs application completion and have confirmed battery grade lithium production by the DLE process before going to the ASX, but equally if those items aren't ready quite yet they would become factors helping to boost the share price after any ASX listing completes...

Anyway, interesting times ahead with loads of news in the pipeline...

GLA

TT - for whatever reason you really seem to want CIZ to fail. Yes, many investors (myself certainly included) won't be up to date with the latest research that's been happening around the world on lung cancer detection, and there may be some excellent mechanisms being developed, and maybe some near completion. But I'd assume that the new Cizzlebio team who have connections in that world and have been attending all this autumn's conferences concerning the latest on lung cancer detection etc will have a much better idea than those of us "with our heads in the sand" of what's in the pipeline... and yet the Cizzlebio team are (as far as we know) still putting their time & money into the CIZ1b story... which would imply that they think it worth it. Ditto apparently with Moffitt.

Surely there's also some advantage too with a blood test, it's minimally invasive and can be sent off to the lab for analysis... the patient doesn't have to travel to the analysis lab himself/herself. There's very low uptake by potential lung cancer patients for having CT screening, likely in part perhaps because of the hassles and time it takes getting to the hospital with an available machine and going through the test procedure. I don't know for sure, but I imagine the situation would be somewhat similar for people in the future getting to a hospital with the right machine & competence for a breath analysis test - and surely it's likely to take a few years before any successfully developed breath analysis machines and competent technicians to administer them are widespread. Will uptake by the average potential lung cancer patient be any different than with the CT scans? Especially if the person might not be presenting any symptoms of lung cancer (as perhaps patients with early stage lung cancer?

Yes, the situation would be a game changer if - in the future - there are portable breath analysis machines widely available and the test procedure is fast & easy and the machine then gives an accurate read out of whatever illness or problem a patient has... but that might be in the future, not now, not next year, and at least CIZ is offering something that might be viable right now (and which is likely to be a significant improvement on the current CT scans). And , for the future, CIZ is trying to develop something as handy and prevalent as the Covid LFT test.

Surely worth a punt of some sort, with the size of punt depending on one's risk tolerance and estimation of the size of likely reward? Hard to know why you're trying to bash the Company, but I do agree it's frustrating having these periods of silence and not having regular updates on what's happening...it increases the sense of risk.

I agree with Highland & VV, same thoughts. For us PIs getting the lung cancer lab test viable, being sold and profitable to all concerned (patients included) is our primary focus, and then hopefully a POC test as the subsequent focus - so far the activities by both CIZ & CIZBIO seem to reflect that. But we’re kept in the dark about a lot of aspects, so we can only wonder about what’s actually going on behind the scenes, what’s exactly happening in the research lab in York, what the recent agreements between CIZBIO & CIZ exactly are etc etc. I don’t think this evident reluctance to share more information is helpful to the sp or to getting CIZ wider known in investment circles, the Company is too opaque for my liking which massively increases my sense of risk with the investment - I feel obliged to take things just on trust and hope, and to spend time on throwaway comments made by AS to try and glean whether my investment is likely to be burnt toast or worth keeping, even eventually profitable, and whether I should hold short-term or long term. This opaqueness has often pushed me close to pulling the plug, and that sense still lingers despite the recent very positive announcements.

However, through the past couple years AS has made these throwaway comments about the CIZib research maybe being applicable to other cancers, with occasional specific mentions of breast cancer, and we PIs don’t know to what stage that research has progressed. I wouldn’t expect PIs to be kept informed in any specific detail about that, although a few general updates for PIs on it would be welcome. But it’s highly likely that BB and the CIZBIO team are much more informed, so that’s why it piqued my interest when I suddenly saw that CIZBIO was attending the Breast Cancer event, a weird and unexpected inclusion amongst the sequence of lung cancer events and given their workload ahead - surely it indicates some greater progress with the research behind the scenes, enough that CIZBIO think it worth initiating contacts in those circles, which to me implies that my CIZ investment might have longer to run … At any rate, these next 9 months look like they are going to be interesting.

Latest Share Chat

Member Info for Hermit

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)